Humbert P, Dupond J L, Agache P, Laurent R, Rochefort A, Drobacheff C, de Wazieres B, Aubin F
Department of Dermatology and Vascular Diseases, Hôpital St Jacques, Besançon, France.
Acta Derm Venereol. 1993 Dec;73(6):449-51. doi: 10.2340/0001555573449451.
1,25-dihydroxycholecalciferol (1,25 (OH)2 D3) causes dose-dependent inhibition of fibroblast growth and collagen synthesis and has numerous immunoregulatory activities. We assessed the effects of oral 1,25 (OH)2 D3 in the treatment of patients with systemic sclerosis (SS). Eleven patients with SS entered an open prospective study. Oral 1,25(OH)2 D3 was given at a mean dose of 1.75 micrograms/day. The effects of the treatment were evaluated using clinical examination and physical measurements. After the treatment period (6 months to 3 years), a significant improvement, as compared with baseline values, was observed. No serious side-effects were observed. These results suggest that high-dose 1,25 (OH)2 D3 may be a useful therapeutic agent for scleroderma.
1,25-二羟胆钙化醇（1,25(OH)₂D₃）可导致成纤维细胞生长和胶原蛋白合成呈剂量依赖性抑制，并具有多种免疫调节活性。我们评估了口服1,25(OH)₂D₃治疗系统性硬化症（SS）患者的效果。11例SS患者进入一项开放性前瞻性研究。口服1,25(OH)₂D₃的平均剂量为每日1.75微克。使用临床检查和体格测量评估治疗效果。治疗期（6个月至3年）后，与基线值相比观察到显著改善。未观察到严重副作用。这些结果表明，高剂量1,25(OH)₂D₃可能是治疗硬皮病的有效药物。
